Pemxcel Adverse Reactions

In clinical trials, the most common adverse reactions (incidence ≥20%) during therapy with pemetrexed as a single-agent were fatigue, nausea and anorexia. Additional common adverse reactions (incidence ≥20%) during therapy with pemetrexed when used in combination with cisplatin included vomiting, neutropenia, leukopenia, anemia, stomatitis/pharyngitis, thrombocytopenia and constipation.
Non-Small Cell Lung Cancer (NSCLC) - Combination with Cisplatin: See Table 4.

Click on icon to see table/diagram/image

The following adverse events were greater in the fully supplemented group compared to the never supplemented group: Hypertension (11%, 3%), chest pain (8%, 6%) and thrombosis/embolism (6%, 3%). For fully supplemented patients treated with pemetrexed plus cisplatin, the incidence of CTC grade 3/4 fatigue, leukopenia, neutropenia and thrombocytopenia were greater in patients ≥65 years as compared to patients <65. No relevant effect for pemetrexed safety due to gender or race was identified except an increased incidence of rash in men (24%) compared to women (16%).